Table 3 Baseline characteristics
Variable | All AKI Stages (N=5731) | Stage 1 (N=4058) | Stage 2 (N=981) | Stage 3 (N=692) |
|---|---|---|---|---|
Age (yr) – median (IQR) | 64 (52–75) | 64 (53–75) | 62 (52–72) | 64 (52–74) |
Female sex (%) | 49.6 | 49.7 | 54.1 | 42.6 |
Race (%) | ||||
White | 83.0 | 82.9 | 84.3 | 81.9 |
Black | 8.9 | 8.7 | 8.4 | 10.7 |
Hispanic | 5.3 | 5.6 | 4.6 | 4.7 |
Other | 2.7 | 2.8 | 2.7 | 2.7 |
Comorbidities (%) | ||||
Malignancy | 28.6 | 30.1 | 27.0 | 21.7 |
Hypertension | 26.3 | 29.4 | 22.8 | 13.3 |
Diabetes Mellitus | 18.6 | 20.1 | 16.0 | 13.6 |
Congestive Heart Failure | 18.1 | 19.4 | 15.2 | 15.0 |
Chronic Pulmonary Disease | 13.2 | 14.6 | 11.8 | 7.2 |
Chronic Kidney Disease | 11.2 | 11.4 | 6.6 | 16.6 |
Chronic Liver Disease | 4.5 | 3.9 | 4.8 | 7.7 |
Laboratory values on admission – median (IQR) | ||||
Serum creatinine, mg/dL | 1.0 (0.8-1.5) | 1.0 (0.7-1.3) | 1.1 (0.8-1.5) | 1.9 (1.0-3.6) |
Hemoglobin, g/dL | 11.1 (9.7-12.7) | 11.2 (9.9-12.7) | 11.1 (9.7-12.8) | 10.3 (8.9-11.8) |
WBCs, 1000/μL | 8.9 (6.3-12.8) | 8.7 (6.3-12.4) | 9.6 (6.5-14.1) | 9.3 (5.9-14.3) |
Albumin, g/dL | 3.5 (3.0-3.9) | 3.6 (3.1-4.0) | 3.4 (2.9-3.9) | 3.2 (2.8-3.7) |